KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Minority Interest (2017 - 2020)

BeOne Medicines (ONC) has disclosed Minority Interest for 4 consecutive years, with $19.6 million as the latest value for Q3 2020.

  • On a quarterly basis, Minority Interest rose 24.37% to $19.6 million in Q3 2020 year-over-year; TTM through Sep 2020 was $19.6 million, a 24.37% increase, with the full-year FY2019 number at $16.2 million, up 11.8% from a year prior.
  • Minority Interest was $19.6 million for Q3 2020 at BeOne Medicines, up from $10.2 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $19.6 million in Q3 2020 to a low of $10.2 million in Q2 2020.
  • A 4-year average of $14.7 million and a median of $14.4 million in 2017 define the central range for Minority Interest.
  • Peak YoY movement for Minority Interest: grew 29.07% in 2019, then plummeted 41.37% in 2020.
  • BeOne Medicines' Minority Interest stood at $14.4 million in 2017, then grew by 0.16% to $14.4 million in 2018, then rose by 11.8% to $16.2 million in 2019, then rose by 21.36% to $19.6 million in 2020.
  • Per Business Quant, the three most recent readings for ONC's Minority Interest are $19.6 million (Q3 2020), $10.2 million (Q2 2020), and $14.8 million (Q1 2020).